---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095063"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:06:09.776884+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates

## Summary
- Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.
- Net loss $31.7M vs $24.0M in Q2 2023; R&D expenses increased to $26.9M from $21.2M.
- Cash, equivalents, and marketable securities $297.7M (plus $5M restricted); funds into Q4 2026.
- FDA granted RMAT designation for TSC-100 and TSC-101 for AML, ALL, MDS post-HCT.
- On track to report one-year heme data and initial solid tumor data by end of 2024.

## SEC filing metadata
- accession: 0000950170-24-095063
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/0000950170-24-095063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017024095063/tcrx-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095063
- JSON: https://secwatch.observer/filing/0000950170-24-095063.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.